PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Documenti analoghi

• Inhibition of EGFR Signaling: All Mutations Are Not Created Equal
  di: Gazdar, Adi F, et al.
  Pubblicazione: (2005)
• Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
  di: Gazdar, Adi F., et al.
  Pubblicazione: (2008)
• Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
  di: Zhang, Wei, et al.
  Pubblicazione: (2009)
• Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
  di: Gandhi, Jeet, et al.
  Pubblicazione: (2009)
• Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer
  di: Gazdar, Adi F.
  Pubblicazione: (2009)